IP Verse

Methods Of Treating Or Preventing Spinal Muscular Atrophy

Patent No. EP3999643 (titled "Methods Of Treating Or Preventing Spinal Muscular Atrophy") was filed by Biogen MA on Jul 16, 2020. The application was issued on Nov 22, 2023.

Patent Summary

A treatment regimen for spinal muscular atrophy (SMA) that rapidly achieves and maintains higher concentrations of antisense compound in patients with SMA. The regimen involves administering a loading dose of the antisense compound at a concentration of 50 mg/mL followed by maintenance doses of 28 mg/mL. This approach enables patients to achieve therapeutic levels of the antisense compound earlier than the approved 12 mg dose of nusinersen, thereby enhancing treatment efficacy. The regimen can be administered intrathecally or intrathecal bolus injections.

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ADALVOAug 22, 2024CASALPRIM CASTELLA
GENERICS UKAug 21, 2024TER MEER STEINMEISTER & PARTNER
TEVA PHARMACEUTICALSAug 21, 2024VON KAUFFMANN
POLPHARMAAug 20, 2024ELKINGTON AND FIFE
SANDOZAug 13, 2024ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3999643

BIOGEN MA
Application Number
EP20753556A
Filing Date
Jul 16, 2020
Status
Granted And Under Opposition
Oct 20, 2023
Publication Date
Nov 22, 2023
External Links
Slate, Register , Google Patents